FOXO3 and breast carcinoma: For example, chemotherapeutic drugs paclitaxel and KP372−1, which are currently used in the treatment of breast carcinoma and acutemyeloid leukemia, can activate FOXO3a by reducing AKT activity [9, 10]; gene-targeted drugs such as trastuzumab and cetuximab enhance the drug sensitivity of drug-resistant tumor cells by activating FOXO3a activity and thus causing overexpression of FOXO3a responsive genes such as Bim, p21CIP1 and p27KIP1 [8, 11, 12].